^
Association details:
| Biomarker: | EGFR wild-type |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Jiataile (sacituzumab tirumotecan) (Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A multicenter, open-label phase II study evaluating the efficacy and safety of SKB264 monotherapy in selected patients with advanced solid tumors.
Excerpt:
......
Source:
Title:
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies
Excerpt:
...only EGFR wild-type NSCLC will be enrolled) Gastric adenocarcinoma or gastroesophageal junction adenocarcinoma (gastroesophageal junction adenocarcinoma is defined as tumor with center located within 5cm below/above the anatomical esophagogastric junction per Siewert classification system) Small cell lung cancer HR+/ HER2- breast cancer Head and neck squamous cell carcinoma (including primary tumor location of oropharynx, oral cavity, hypopharynx, or larynx....
Trial ID:
More C2 evidence
Source:
Title:
Phase II clinical trial of SKB264 in combination with other treatments for patients with advanced or metastatic non-small cell lung cancer.
Excerpt:
......
Source:
Title:
SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors
Excerpt:
...For subjects enrolled in Part I Cohort 3, the following criteria must be met: ①NSCLC confirmed by tumor histology to be EGFR wild-type and negative for ALK fusion gene; ②...
Trial ID:
Source:
Title:
Phase II clinical trial of SKB264 as monotherapy or in combination therapy for patients with advanced or metastatic non-small cell lung cancer.
Excerpt:
......
Source:
Title:
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
Excerpt:
...Cohort 1: Patients with locally advanced/metastatic NSCLC with wild-type EGFR and negative ALK fusion gene,...
Trial ID:
Less C2 evidence
Source:
Title:
SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: Efficacy and safety data from a phase 2 study.
Published date:
05/31/2023
Excerpt:
For EGFR wild type subgroup (previously received median 2 lines of therapy including anti-PD-1/L1), the ORR was 26% (5/19), DCR was 89% (17/19), median PFS was 5.3 mo, and 9-month OS rate was 80.4%...SKB264 at 5 mg/kg Q2W demonstrated encouraging anti-tumor activity and manageable safety profile in pts with relapsed or refractory locally advanced/metastatic NSCLC.
DOI:
10.1200/JCO.2023.41.16_suppl.9114